



Euro BioFairs Compass

Winter Edition 2016/17

II Guide to Life Sciences Events

CE INNOVATION **FUTURE**



SPECIAL

Join the European Biotechnology Network!



The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe. This non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.

Do you want to know more about the advantages of a (free) membership? Just have a look at our website.



European Biotechnology Network AISBL
Rue de la Science 14b | 1040 Brussels, Belgium
Tel: +32 (0)2 733 72 37
office@european-biotechnology.net
www.european-biotechnology.net

CORPORATE MEMBERS 1/16



Mark your calendar

EUROBIOFAIRS COMPASS Every manager, scientist, or business developer has a very individual, specific network and so their must-attend events differ significantly. Where to meet potential new partners and how to widen one's scope besides the well-known terrain can be quite difficult to determine. EURO BIOFAIRS COMPASS will help you navigate the European meeting jungle in H1/2017.



Held in San Francisco, the **Biotech Showcase** (9–11 January 2017) networks biotechs with investors (p. 38).

The worldwide threat of antimicrobial resistance in medicine will be the focus of the first edition of the **Berlin Conference in Life Sciences** (24 February, British Embassy). Decision makers from Big Pharma and biotechs, policy makers, regulators, payors, business developers, and investors will meet in Berlin to explore how to incentivise companies to develop novel antibiotics that can break the ever-emerging drug resistance of multiresistant strains (p. 40).

Insight into microbiotic medicinal products will be provided for the very first time at **The 1st Pharmabiotics Global 2017** (15–17 March) in Paris (p. 42). Converting science on how our microbiome impact health in medicines, regulatory affairs, and the market potential, together with partnering opportunities, will be only a few of the topics addressed at the three-day conference. Accompanied by an exhibition, the novel format is set to establish the

premier global meeting point for representatives from biotech, food, Big Pharma, and R&D.

The sister meeting to biotech industry's largest partnering event, **EBD's Bio-Europe Spring 2017** (20–22 March), on the other hand, will provide the perfect meeting point for biotechs, investors, and pharma executives in Barcelona (see p. 44).

Keep your suitcase packed

For those in the healthcare sector, a visit to Glasgow might be unavoidable. This year's **DIA BioVenture Day** on 28 March will present another conference premiere, one day prior to the main event, the DIA Annual EuroMeeting. At the DIA BioVenture Day (see p. 48), stakeholders will discuss answers to the question "Is the current Bioventure paradigm delivering return for patients, investors, and the health care system?". With the DIA Annual EuroMeeting under one roof, TBC Glasgow is certain to turn into a global healthcare village.

Some days later, on 30–31 March, all clinical research whiz kids should prick up their ears and head to Berlin. Learn how to improve your workflow in an ever-changing regulatory environment at the DGPharmMed's **33th Annual Congress on Pharmaceutical Medicine** (see p. 46). Explore new approaches to biomarkers, gene therapy, medical devices, and much more.

A meeting that still has a major impact kicks off on 4 May at Congress Centre Basel, which will host the nation's most important biotech event, the **Swiss Biotech Day** (see p. 50). As in previous years, the new Swiss biotech report will shine a light on the industry's status in the country. Due to the growth of the sector, the Swiss Biotech Day moved to Basel Congress Centre last year.

Chemical and biotech engineers should block off the days from 10–11 May. At the **International Conference on Bio-Based Materials** in Cologne (see p. 52), experience first hand exactly how an established market is being reshaped by visionaries from the chemicals and plastics businesses.

One of the hottest topics not yet in biomedicine but already in drug development will be in the limelight from 16–17 May. Experts from all over the world will present the latest applications of the ground-breaking CRISPR-Cas9 gene editing technology in exploring stem cell development. Stem cell-derived cancer models and 3D organoids will be another focus at the **International Meeting of the Stem Cell Network NRW** in Münster (p. 54). It's a must for R&D and biopharma professionals. ■



BIOTECH SHOWCASE™

JANUARY 9–11, 2017
SAN FRANCISCO, CA, USA

9–11 January 2017
Hilton San Francisco Union
Square, San Francisco, USA

The one not to miss

BIOTECH SHOWCASE The 9th annual conference is where innovation meets money. San Francisco's exclusive investor event takes place during healthcare's busiest week of the year. It is considered to be a critical strategic benchmark for the industry's most innovative biotech companies to connect with global life science decision makers and investors.

Held annually in San Francisco during healthcare's busiest week, on 9–11 January, 2017, Biotech Showcase™ facilitates opportunities for innovative public and private biotech companies to engage with global life science decision makers from private equity, angel, and venture investors.

In the global pharma and biotech sector, dealmaking and partnering is of growing significance. In addition, although volatile conditions exist in the

US public markets, they are still attractive for biotech companies, because of the substantial number of its life science-orientated investors. According to the most recent "Analysis of European public biotech companies," published by BIOCOM in November 2016, the 26 European biotech firms listed on Nasdaq raised higher IPO volumes and attracted more capital on average in follow-on financings than their counterparts on European stock exchanges.

In 2016, such US-sourced capital averaged €43m, more than twice as much as in Europe (€17m). Considered as one of the most important investor's conferences, Biotech Showcase™ offers all life science companies – be they international biotech firms, public, mid- and small-cap life science companies, or venture and angel-backed private companies – an excellent opportunity to present on a broader stage. More than 3,000 attendees from across the globe are expected to take part in one-on-one meetings and participate in informal networking.

A robust programme complements this activity, with panels and workshops focused on the latest industry trends, such as regenerative medicine and digital health, featuring key biotech leaders, investors, pharma executives, and other industry advisors. Don't miss the most impactful week of the year. Biotech Showcase: Where Innovation Meets Money. Register now. ■

A critical time

GREETING January is a critical time for global life science companies to



review their business strategies, regroup, and make plans for raising capital in the year ahead.

Biotech Showcase™ 2017 is the annual,

exclusive event for investors and networking, which sets the tone for drug development dealmaking for the rest of the year.

Join hundreds of innovative biotech companies and global biotech investors in San Francisco 9–11 January, 2017.

Anna Chrisman
Group Managing Director
EBD Group

QUICK FACTS

Showcase

More than 300 mid- and small-cap private and public firms will present their companies. Request a slot online.

Online registration

You may register online until 6 January, 2017. Qualified investors attend for free. Please visit: www.biotechshowcase.com

INNOVATION MEETS MONEY

at **BIOTECH SHOWCASE™** the exclusive
investor and networking event

JANUARY 9–11, 2017 IN SAN FRANCISCO

Biotech Showcase is a “must attend” investor and networking event held during the industry's most important week of the year. The event brings together 3,000+ executives representing innovative life science companies and major players in the drug development arena.



REGISTER NOW:
biotechshowcase.com

Co-produced by

EBD
GROUP

 **DEMY
COLTON**



British Embassy
Berlin

24 February, 2017
British Embassy, Berlin,
Germany

Fighting bad bugs

BERLIN CONFERENCE ON LIFE SCIENCES The Berlin Conference opens the meeting season every year in February. In its tenth year, the event highlights innovative strategies from European firms to fight antimicrobial resistance. Held in the British Embassy in the German capital, the conference provides insight into the challenging antimicrobials market.

Healthcare systems worldwide are in growing need of efficiently combating antimicrobial resistance (AMR). In May 2016, the AMR report, published by British economist Jim O'Neill, documented this situation by analysing current pipelines and research activi-

ties. According to O'Neill, there is an urgent demand for an efficient drug development process, in the private pharma and biotech sectors, as well as in the academic ones. However, to date, there are only a few big pharma companies left that are active in the field. Just recently, British pharma company AstraZeneca made a strategic withdrawal.

On the other hand, there are dozens of small and medium-sized enterprises (SME) working on new technology platforms or novel classes of antibiotics, particularly in Europe. Among them are publicly-listed companies such as British Redx or Motif Bio, as well as privately held firms, such as German Aicuris, Swiss Bioversys, and Danish Antibiotx. In 2015, a group of more than 40 European SMEs formed the BEAM alliance to demonstrate the excellence in the field. Among the members is also Ger-

man-French company Allecra Therapeutics, which raised €22m in a series B investment round in June of this year, convincing venture capitalists from Forbion Capital Partners, Edmond de Rothschild Investment Partners, and EMBL Ventures, as well as new investors from Chinese Delos Capital.

Another indicator of the growing activity in the area are several, new research results that were published this year, highlighting novel antibacterial mechanisms or compounds that might be effective against multi-resistant bugs. This development is further supported by new, global public-private partnerships, such as US-initiated CARB-X, which will invest more than US\$350 million in the next five years to accelerate the progression of innovative antibacterial products into clinical trials. From a European perspective, British AMR centre which was established in May 2016, is a major partner.

Against this backdrop, the Berlin Conference, organised jointly this year by BIOCUM AG and the Department of International Trade at the British Embassy, is designed to provide an overview of the dynamic antimicrobials market. This will be complemented by sessions covering R&D highlights, drug development challenges, IP and market access issues, as well as financial and economic topics.

› QUICK FACTS

Why attend?

More than 1,000 satisfied attendees since 2008, coming from industry (60%), academia (30%) and other organisations (10%) – with 75% executive and senior management

Registration

Early bird and special rates available. Please visit: www.berlin-conferences.com

10th Berlin Conference on Life Sciences

Novel Antimicrobials



24 February 2017, British Embassy Berlin, Germany

Over its ten-year history, the Berlin Conference on Life Sciences has become a must-attend event for Life Science decision makers, business developers, investors and legal experts. The upcoming conference will explore the exciting market and challenging conditions for the development of novel antimicrobials.

- › Antimicrobial Market – Industry overview, SME engagement & financial insights
- › Technology Perspective – New approaches to efficiently combat antimicrobial resistance
- › Legal Environment & Reimbursement – The challenges of bringing antimicrobials to the market
- › R&D Trends – Research and development beyond antibiotics & public-private partnerships
- › Start-up Pitch – Investors talk & new business models in the field

Speakers from Allecrea, Antibiotx, Bioversys, Polyphor, Madam Therapeutics, Nosopharm, Forbion Capital Partners, Boehmert & Boehmert as well as from the British AMR centre already confirmed their attendance. Please find an initial agenda of the programme and the registration form at: www.berlin-conferences.com

Principal Partner:



Sponsor:



Supporting Partner:



Media Partner:





15-17 March, 2017
Palais Brongniart, Paris,
France

Microbiome in focus

PHARMABIOTICS GLOBAL Focusing on late stage science, product development and market access, Pharmabiotics Global 2017 consists of a conference, exhibition and the first-ever partnering forum dedicated to the international microbiome community.

Recent research has shown the importance of communication within the human microbiome (i.e. the bacteria inhabiting our body) in the maintenance of good health. Imbalances within this communication can lead to a range of gastrointestinal, vaginal, skin and autoimmune diseases. As our understanding of this complex ecosystem of microbes grows, it is becoming increasingly apparent that the microbiota offers huge potential to the future of healthcare. Pharmabiotics Global 2017

is a new industry initiative aimed at therapeutic approaches via the Human Microbiota.

Conference Themes include phage therapies, fecal microbiota transfer, development technology, EU and US product regulations, urogenital pathologies and the upper-respiratory tract. Running alongside the Conference, delegates can participate in back-to-back private meetings, through our unique business networking software, bringing together the necessary play-

ers to transform the microbiota into a therapeutic reality: academics looking for commercial partners, commercial enterprises looking to increase their research pipeline, pharma companies searching for new therapies, biotech start-ups searching for funding, financiers searching for investment opportunities, distributors looking to expand their product portfolio, and service providers for business development

Pharmabiotics Global is organised by the Pharmabiotic Research Institute (PRI), a non-profit EU Trade Association that takes a collaborative approach to assisting its members with the developments of their Microbiotic Medicinal Products.

If you are interested in treating diseases via the Microbiota, PRI invites you to Palais Brongniart, the Historic French stock exchange in Paris, 15-17 March for three days of networking, exchange and turning science into therapeutic realities. ■

A Key Event

GREETING *The Pharmabiotic Research Institute is positioned at the cross roads of research and application, science and law, health and pharma. We therefore have the ambitious task of trying to serve the best of these worlds, in*



terms of both content and networking. With the first Pharmabiotics Global event coming up in March, it appears that we have already achieved this: Looking at the conference programme and the list of organisations attending the Partnering Platform and exhibition, it is developing into the key event for microbiome related therapies.

Dr. Magali Cordailat-Simmons
Pharmabiotic Research Institute
Regulatory & Scientific Affairs Director

QUICK FACTS

WEBSITE

pharmabioticsevent.com

CONTACT

Nick Gallo, Event Director
I-Squared Communications Ltd
Covent Garden, London, UK

Email: nickgallo@pharmabiotic.org
Phone +44 (0) 20 3286 0167

PARIS
MARCH 15-17



Pharmabiotics Global2017



Conference



Partnering



Exhibition

Microbiotic Medicinal Products



www.pharmabioticsevent.com



20–22 March, 2017
Barcelona, Spain
CCIB Convention Centre

Reunion in Barcelona

BIO-EUROPE SPRING The 11th annual BIO-Europe Spring international partnering conference will return to Barcelona. This premier, annual gathering always occurs at one of Europe's most innovative biopharma clusters.

The annual BIO-Europe Spring event is highly regarded among companies across the life sciences value chain, from large biotech and pharma companies, to financiers and innovative start-ups. For the 11th edition in March 2017, the international partnering conference will return to Barcelona, Spain.

Executive decision makers from international drug development companies attend to participate in partnering meetings, one-to-one, private business development, and discovery meetings that occur throughout the event. BIO-Europe Spring has one of the largest, most dy-

namic platforms facilitating industry partnering. Leading pharmaceutical companies sponsoring the event send teams of scouts to BIO-Europe Spring to engage with new and innovative products, ideas, and companies. Past sponsors include big names in pharma, such as AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Merck, Merck Serono, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Shire, Takeda, and many others.

"We are very excited to bring BIO-Europe Spring once again to Barcelona," said Anna Chrisman, Group Managing

Director of EBD Group. "The Barcelona area is a world-class, research destination, with 20 science and technology parks and 60 research centres focused on life science, and over 450 companies in the sector. The quality and variety of attending companies is always very high. This translates to more partnering opportunities and more potential deals."

Company presentations are the lifeblood of the event, bringing together global innovators and visionaries with potential partners. BIO-Europe Spring also features a diverse list of industry leaders speaking on panels and workshops.

The 2016 event boasted over 12,500 scheduled one-to-one meetings with 3,500+ licensing opportunities posted from among 1,300 companies from over 45 countries. Partnering remains the core drug development strategy of big pharma and biotech in the current economy. ■

Join us in Spain!

GREETING *BIO-Europe Spring 2017 is key to the business strategy of global biotech, pharma, and investors, focusing on collaboration opportunities and deal-making.*



Barcelona is a world-class research destination with over 60

research centres focused on innovative life sciences. The event brings a high quality and wide variety of companies to present their licensing opportunities directly to potential partners, resulting in alliances that literally change the world.

See you in Barcelona in the spring!

Anna Chrisman
Group Managing Director
EBD Group

QUICK FACTS

ONLINE REGISTRATION

Please visit: ebdgroup.knect365.com/bioeurope-spring/
The Early Bird Discount is available through January 20, 2017

COMPANY PRESENTATION

The deadline to submit an application to present your company is December 2, 2016

BIO-EUROPE SPRING®

BARCELONA, SPAIN // MARCH 20-22 2017

With a focus on European innovation and global collaboration, BIO-Europe Spring® is the premier springtime partnering conference bringing together a “who’s who” from biotech, pharma and finance in the most innovative biopharma clusters in Europe.

Expected numbers for next event:

- 2,400+ attendees
- 12,500+ one-to-one meetings
- 2,700+ licensing opportunities posted

Save **EUR 100**
on Registration
with code
BES17-Biocom

FIND OUT MORE! ebdgroup.com/bes

Produced by

EBD
GROUP

Supported by

Bio Biotechnology
Innovation
Organization



23–24 March, 2017
Steigenberger Hotel am Kanzleramt, Berlin, Germany

Off to new pastures

ANNUAL CONGRESS ON PHARMACEUTICAL MEDICINE Clinical development: the name says it all. In order to keep up to date, we have to stay abreast of changes. At this congress, some of the latest topics in the development of medicinal products and medical devices will be presented.

The pharmaceutical landscape is changing, and one has to keep pace with various trends while people, science, and the regulatory environment are moving forward. The future looks different, but does this mean for better or for worse? The 2017 Annual Congress on Pharmaceutical Medicine will help to answer this question.

The event provides the opportunity to look closer at selected trend-setting topics. In a total of five symposia and a panel discussion, 20 experts will share their

experiences with up to 300 participants. They will share their insights gained and lessons learned, as well as in their visions of areas like biomarkers, gene therapy, the blend of clinical trials, and the regulatory area, as well as the rapidly expanding subject of medical devices.

In the panel discussion, the compatibility of money, corruption, and data protection will be discussed. In addition, in a "Hot topics" session, talking points such as the Brexit, health technology assessment, and reimbursement strategies, as well as the privacy shield, will be presented. To complete the picture, a "science meets business" contribution will introduce a group of young scientists, eager to follow in the experts' footsteps.

DGPharMed is thrilled to present this interesting and inspiring mix of current and future-focused topics in pharmaceutical medicine. Participants can benefit from the event's early bird rates valid until January 20, 2017: €490 for DGPharMed members and €640 for non-members. The organisers look forward to welcoming you in the German capital on 23–24 March, 2017. ■

Stay on top!

GREETINGS *While the pharmaceutical landscape around us develops further, we are called upon to find new pathways in order to maintain oversight. At the 33rd Annual Congress on Pharmaceutical Medicine, we invite you to accept the dare and explore new approaches to biomarkers, gene therapy, medical devices, and other advanced topics.*



It is not unusual to be facing new regulations, but still we do not know exactly how to cope with obligations originating from recently developing regulations. By sharing best practices in conducting clinical trials and pharmacovigilance, the annual DGPharMed congress can help to manage such challenges.

On behalf of the programme committee and as the DGPharMed host, I cordially invite you to join us at the Steigenberger Hotel am Kanzleramt in Berlin on 23–24 March 2017 to listen to interesting presentations and participate in active and lively discussions on forward-looking subjects. The full programme will soon be available online at www.dgpharmed.de/veranstaltungen/.

Dr. Susanne Kienzle-Horn
Bundesvorsitzende DGPharMed e.V.

› QUICK FACTS

Exhibition

Interested to exhibit at this event?
Please contact: aussteller@degepe.eu

Congress rationale

Keep pace with latest trends and join trend-setters in important development and regulatory areas, including biomarkers, gene therapy and medical devices!

33rd DGPharMed Annual Meeting

*Drug and product development
tomorrow: Striking new paths?*

March 23–24, 2017 · Berlin, Germany
Steigenberger Hotel am Kanzleramt

Looking for
exhibition space?
Get in touch with us:
aussteller@
degepe.eu

Symposia

Thursday, March 23, 2017

- Biomarker – Now and in future?
- Science meets business –
Presentation: Young Scientists
- Hot topics
- No conflict – no interest?
Money, Corruption and Privacy

Congress Fees*

DGPharMed-Members: 490,- €

Non-Members: 640,- €

*Early-Bird-Rate valid until January 20, 2017. Bookings from January 21, 2017: 590,- € (Members) / 740,- € (Non-Members).

Organizing Committee

Diane Seimetz, Bettina Ziegele, Bernard Brandewiede, Jan Heun, Christian Schneider, Carsten Wieser

Friday, March 24, 2017

- Medical devices – What's new?
- What's up in Clinical Trials and the Regulatory
Arena?
- Gene therapy – Our future?

Program flyer online shortly at www.dgpharmed.de



DIA

28 March, 2017
Glasgow,
United Kingdom

Driving innovation

DIA BIOVENTURE DAY DIA is establishing a new platform to support health care innovation by connecting all stakeholders that are now key to the success of BioVentures, and to continued patient access to innovation.

The development strategies of many pharma companies are now reflecting a “me-too”-approach, where new products mainly feature incremental increases in safety or efficacy but rarely true therapeutic innovation. The impact of these micro-innovations on the current pharmaco-economic models is not well understood, although the consequences for sustained reimbursement and access are likely to be serious.

To answer the question “Is the current Bioventure paradigm delivering return for patients, investors, and the health care system?”, DIA is hosting the first BioVenture Day one day prior to its European flagship conference, the

EuroMeeting. There is already excitement in the key networks regarding this new platform for finding solutions for the looming issues of health care system financing.

Venture capitalists, health care insurers, heads of biotech companies, leaders from big and small pharma, patient advocates, policy makers, payers, as well as foundations, will convene to find answers to challenges that the health care product development sector is facing regarding the funding of innovation and the reimbursement of medicines, which is key to sustained patient access to innovative care.

In a mix of presentations and panel discussions, top level speakers will explore how to best address the problem of unmet medical need and innovative funding models, discuss the reimbursement of innovation and health system financing. Speakers and participants will review the efficiency and connectivity of bioventure approaches to existing development pipelines, health care product regulation, and value assessments in order to accelerate true innovation in health care. ■

Focus on funding

GREETING *The DIA Bioventure Day is a unique opportunity to engage with the individuals you don't meet elsewhere. We initiated this new event after DIA was approached by patient advocates and venture capitalists, asking us to facilitate discussion between these actors and involve decision-makers from regulatory and reimbursement perspectives.*



The event will discuss funding of health care innovation from a holistic point of view in an attempt to find solutions and increase mutual understanding of the issues. We will also bring in stakeholders who have a disruptive role in funding and driving innovation, such as philanthropic investors and public investment banks. The day will conclude with a moderated poster session that will allow innovators to present their novel business cases and success stories.

This is a “must-attend” event for anyone that wants to understand the reality of health care innovation from funding to access and re-imbursement.

Holger Adelmann
Senior Vice President & Managing Director
DIA, EMEA

▶ QUICK FACTS


Contact

Email: EMEA@DIAGlobal.org
Phone: +41 61 225 51 51

More information

DIAGlobal.org/BioVentureDay

DIA 29TH ANNUAL EUROMEETING GLASGOW | 2017 29-31 MARCH



TRANSLATIONAL HEALTH CARE **FROM BENCH TO BEDSIDE - AND BACK**

10 Themes to Build Your EuroMeeting Experience

- Theme 1: Globalisation of Global Product Health Care Development - What are the Current Successes and Challenges?
- Theme 2: Innovation of Global Product Health Care Development - What are the Key Success Factors?
- Theme 3: Current Challenges in Clinical Research
- Theme 4: eHealth/Big Data/Master- and Reference Data Management
- Theme 5: Pharmacovigilance
- Theme 6: Regulatory Science
- Theme 7: Medical Devices and Combination Products
- Theme 8: HTA, Value and Access
- Theme 9: Information on Medicines, Medical Writing and Dossier Generation
- Theme 10: Special Populations

2,500+
PARTICIPANTS

120+
EXHIBITING
COMPANIES

LEARN MORE
DOWNLOAD
PROGRAMME



DIAMOND Sessions

- Major European Regulatory Science Challenges
- Current Trends and Solutions in Global Clinical Operations
- Global Regulatory Convergence
- Clinical Development Partnering 2.0

To download the programme and to register visit
DIAGlobal.org/EM2017



SWISS+
BIOTECH™

4 May, 2017
Congress Centre Basel
Basel, Switzerland

Capital of biotech

SWISS BIOTECH DAY The Swiss Biotech Day has long become the standard annual get-together of the Swiss biopharmaceutical industry. And Basel, as one of the most vivid cities in terms of biotechnological and pharmaceutical research, development and production, proved to be the ideal location.

He was the first to use chemicals and minerals for therapeutic purposes, he propagated empirical knowledge as the basis of medical diagnostics and treatment, and he knew about the importance of dosage for efficacy and side effects of any given drug. About 500 years ago, Philippus Aureolus Theophrastus Bombastus von Hohenheim, commonly known as Paracelsus, studied medicine and pioneered here, in Basel, what is now the basis of modern medicine.

Therefore, which location could fit better to host the Swiss Biotech Day at 4 May, 2017, than Basel. 500 senior executives from Swiss and European biopharmaceutical companies and senior scientists from leading academic institutions will come together at the Congress Centre Basel, not least to demonstrate, how far medicine have come since Paracelsus' times, and how biotechnology – a field Paracelsus couldn't even anticipate – is going to shape the next 500 years.

The event will traditionally start with the General Assembly of the Swiss Biotech Association, followed by the keynote address of Lonza AG's CEO Richard Ridinger and the presentation of the Swiss Biotech report 2017. During the afternoon, parallel sessions will be presented by partners of the Swiss Biotech Day and offer insights into more specific issues within the life sciences and drug development: Analyses and predictions of publicly listed biotech companies and financing opportunities will be featured in the "Analyst and Investor" track, accompanied by the "Emerging companies", "Highlights in Research" and "International Relations" tracks. ■

› QUICK FACTS

Registration

www.swissbiotechday.ch/keep-me-informed
Phone: +41-43-508-1121
register@swissbiotechday.ch

Highlights:

- › Keynotes by industry authorities
- › Swiss biotech report 2017
- › In-depth parallel sessions
- › One-on-one partnering

The place to be

GREETING *More than 200 companies in Switzerland develop biopharmaceutical products, making it the country's largest export sector. 83% of these exports were contributed by pharmaceuticals, with a significant proportion of biotech products. For some of the largest Swiss companies such as Novartis, Syngenta or Roche as well as a growing group of innovative biotechnology start-ups, Switzerland – and especially Basel – is the hub of their global R&D network and manufacturing sites. It is here, where the Swiss Biotech Day (SBD) belongs, the annual meeting for key authorities within this dynamic field of applied life sciences.*



Now in its 19th year, the SBD is not just the place to be for members of the Swiss Biotech Association, who traditionally meet there for the association's Annual General Assembly. As always, the event targets entrepreneurs, investors, researchers, analysts, political decision makers and industry stakeholders. Attendees will be able to meet key stakeholders and friends via SBD's partnering systems or enjoy presentations from key authorities like Richard Ridinger, the CEO of Lonza AG.

See you in Basel!

Domenico Alexakis
CEO, Swiss Biotech Association

SWISS BIOTECH DAY 2017

The leading Life Sciences Conference in Switzerland and Annual General Assembly of the Swiss Biotech Association



4 MAY 2017

Basel Congress Center

The Swiss Biotech Day is the leading biotechnology conference in Switzerland.

Programme highlights in 2017 will be keynotes by Lonza and Johnson & Johnson, in addition to dedicated one-to-one partnering opportunities and an exhibition. The parallel session in the afternoon will focus on publicly listed biotech companies, emerging biotech companies, highlights in research and international relations.

So don't miss out to meet around 500 senior experts from industry and academia in the life science sector from across Europe.

Find more information on the event and a registration form at www.swissbiotechday.ch

Sponsors:



Media Partner:



10 – 11 May 2017
Cologne,
Germany

Bio-based trends

10TH INTERNATIONAL CONFERENCE ON BIO-BASED MATERIALS From 10–11 May 2017, this well-established, worldwide meeting point will bring an estimated 300 experts and 30 exhibitors to Cologne, Germany to discuss innovations in industrial biotechnology.

Market leaders will showcase the latest developments and trends in bio-based building blocks, polymers and industrial biotechnology at this preeminent international conference. Alongside leading companies, representatives from political bodies and associations will share insights into the latest national and regional policies, strategies, and visions.

Bio-based building blocks for polymers will be one focus of the conference. A variety of new bio-based

building blocks, such as furan derivatives, succinic acid, and 1,4-butanediol, are just entering the market and, thus, provide the opportunity to create brand-new bio-based polymers. Oleochemistry will also be a big draw at the conference, as it offers a wide variety of innovative solutions for manufacturing detergents, lubricants, paints, and coatings, for example.

As an event that strives to highlight innovation, the conference will again

dedicate a session to young and promising start-up companies. High-potential start-ups from the fields of bio-based chemistry, polymers, and biotechnology are invited to present their business to industry at this start-up session and make contact with potential investors.

To further honour and acknowledge new developments in the innovative bio-based chemicals and materials industry, every year, the participants of the conference choose the winner of the Innovation Award "Bio-based Material of the Year." The competition focuses on new developments in the bio-based economy that have had (or will yet have) a market launch in 2016 or 2017. Producers and inventors of innovative, bio-based materials are invited to submit their application by the end of February.

Register before the end of the year and take advantage of an exclusive, early bird discount of 15%. ■

Get involved

GREETINGS *New bio-based building blocks and polymers are key drivers of innovative and sustainable developments in the industrial biotechnology industry as a whole. In cooperation with prestigious partners we provide a perfect platform for our participants. Meeting*



tools, an extensive exhibition, and cutting-edge topics guarantee an excellent overview, with successful business contacts and networking in a cheerful atmosphere.

Don't miss the "10th International Conference on Bio-based Materials," 10–11 May 2017 in Cologne, Germany. We're looking forward to meeting you in May 2017.

Michael Carus
CEO
nova-Institute

QUICK FACTS

ONLINE REGISTRATION

<http://bio-based-conference.com>

CONTACT

Dominik Vogt
dominik.vogt@nova-institut.de

VENUE

Maternushaus
Kardinal-Frings-Str. 1–3
50668 Cologne

10th International Conference on **Bio-based Materials**

10–11 May 2017, Maternushaus, Cologne, Germany

Focus: ++ Bio-based building blocks for polymers ++ Oleochemistry ++ Innovation Award ++ Start-ups ++



HIGHLIGHTS OF THE WORLDWIDE BIOECONOMY:

- Policy and Markets
- Bio-based Building Blocks and Polymers
- Biorefineries and Industrial Biotechnology

The 10th International Conference on Bio-based Materials is aimed at providing international major players from the bio-based building blocks, polymers and industrial biotechnology industries with an opportunity to present and discuss their latest developments and strategies. The conference builds on successful previous conferences: 300 participants and 30 exhibitors mainly from industry are expected.

Contact



Dominik Vogt

Conference Manager

+49 (0)2233 4814-49

dominik.vogt@nova-institut.de

Organiser




Institute
for Ecology and Innovation



Pictures: J.Rettenmaier & Söhne, BASF, nova-Institute

More information at: bio-based-conference.com



9th International Meeting
Stem Cell Network NRW

16–17 May 2017
Halle Münsterland,
Münster, Germany

Stem cell congress

THE 9TH INTERNATIONAL MEETING OF THE STEM CELL NETWORK NRW

will take place on 16–17 May 2017 in Münster. The network's program committee has identified the latest themes in the field of stem cell research and has invited their internationally leading experts to take part.

The recent advent of genome-editing technologies has heralded a new scientific paradigm, which allows the sequence of the human genome to be precisely manipulated so as to achieve therapeutic effects. In Münster, Chad Cowan (Boston) will explain the benefit of converting novel genetic findings into the knowledge needed to develop therapies for treating metabolic diseases.

Establishing organoids for disease modelling enables researchers to investi-

gate the entire canon of pathologies accompanying a disease or to test drug candidates. Jason Spence (Michigan) uses human pluripotent stem cells to generate 3D tissues, e.g., human intestinal organoids, in order to study human intestine development, differentiation, and disease. Among the pioneering achievements of Hans Clevers (Utrecht) is the discovery of intestinal stem cells, which has a profound impact on in-vitro organ culture, but also on stem-cell-based therapeutics in the treatment of cancer and in regenerative medicine.

The discovery of the first oncogene (Ras) and the first tumour suppressor gene (Rb) in humans by Robert Weinberg (MIT, Cambridge) has fundamentally changed our understanding of the causes of carcinogenesis. He will share his latest research with us in Münster.

We will also welcome Michele De Luca (Modena), whose name is associated with stem cell therapies for treating patients with skin burns, stem cell transplants for patients suffering from junctional epidermolysis bullosa, and transplants for treating corneal degeneration. ■

Congress 2017

GREETINGS *The Stem Cell Network NRW is holding its 9th International Meeting in Münster, Germany (16–17 May, 2017). The congress will cover the latest developments in international stem cell research. In 2017, the focus will be on genome editing, 3D organoids, and the use of stem cells in regenerative medicine. There will also be talks on disease modelling, tumour initiating cells, totipotency and pluripotency, epigenetics, and stem cell niches. We look forward to welcoming Hans Clevers for the keynote, as well as Michele De Luca, Robert Weinberg, Zena Werb, and many other outstanding speakers. The organizers particularly welcome junior scientists to present scientific posters (outstanding abstracts will be selected as talks in the main conference program), and they will be able to discuss their work with our speakers at Meet-the-Expert events. Funding from the Ministry of Innovation, Science, and Research NRW enables us to invite world-class speakers and makes it possible for delegates to attend the congress free of charge.*



Dr. Anne Do Lam-Ruschewski
Managing Director
Stem Cell Network NRW

► QUICK FACTS

ONLINE REGISTRATION

www.congress.stemcells.nrw.de

CONTACT

Stem Cell Network NRW
Phone +49-211-896 4042/-4043
info@stemcells.nrw.de

VENUE

Albersloher Weg 32
48155 Münster, Germany



9th International Meeting

Stem Cell Network
North Rhine-Westphalia

May 16–17, 2017
Münster, Germany

- Sessions on Disease Modeling, Genome Editing, 3 D Organoids, Stem Cells and Regeneration
- Opening lecture by Hans Clevers
- Lectures by Michele De Luca, Alexander Meissner, Robert Weinberg, Zena Werb and many more
- Poster Session, abstract submission due by March 1, 2017
- Company Exhibition
- Satellite Symposium on Bioinformatics

Congress attendance is free of charge.

Please register at:
www.congress.stemcells.nrw.de

funded by:

Ministry of Innovation, Science
and Research of the German State
of North Rhine-Westphalia



Stem Cell Network
North Rhine Westphalia